Biogen Inc
NASDAQ:BIIB 10:24:30 AM EDT
Products
BRIEF-Eisai and Biogen Announce Lecanemab Receives Priority Review Status In Japan
Published: 01/29/2023 23:58 GMT
Biogen Inc (BIIB) - Eisai Co.
, Ltd.
(headquarters: Tokyo, Ceo: Haruo Naito, "eisai") and Biogen Inc. (nasdaq: Biib, Corporate Headquarters: Cambridge, Massachusetts, Ceo: Christopher A. Viehbacher, "biogen") Announced Today That an Application for Manufacturing and Marketing Approval for Lecanemab (generic Name, U.S. Brand Name: Leqembi™), an Anti-amyloid-Β (aΒ) Protofibril* Antibody, in Japan Has Been Designated for Priority Revie.
Lecanemab Receives Priority Review Status in Japan.
, Ltd.
(headquarters: Tokyo, Ceo: Haruo Naito, "eisai") and Biogen Inc. (nasdaq: Biib, Corporate Headquarters: Cambridge, Massachusetts, Ceo: Christopher A. Viehbacher, "biogen") Announced Today That an Application for Manufacturing and Marketing Approval for Lecanemab (generic Name, U.S. Brand Name: Leqembi™), an Anti-amyloid-Β (aΒ) Protofibril* Antibody, in Japan Has Been Designated for Priority Revie.
Lecanemab Receives Priority Review Status in Japan.